Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 10/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.40 |
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1780970 | 0.94 | MAPT (0.43) | MAPTLMNAHTTTP53NPSR1 | |
| SCHEMBL1780745 | 0.94 | MAPT (0.43) | MAPTLMNAHTTTP53NPSR1 | |
| SCHEMBL1780808 | 0.93 | MAPT (0.42) | MAPTLMNAHTTTP53NPSR1 | |
| SCHEMBL1779931 | 0.93 | MAPT (0.45) | MAPTLMNAHTTTP53NPSR1 | |
| SCHEMBL1782337 | 0.93 | MAPT (0.42) | MAPTLMNAHTTTP53NPSR1 | |
| SCHEMBL1782494 | 0.92 | MAPT (0.42) | MAPTLMNAHTTTP53NPSR1 | |
| SCHEMBL17676707 | 0.91 | MAPT (0.45) | MAPTLMNAHTTTP53NPSR1 | |
| SCHEMBL1782132 | 0.90 | MAPT (0.41) | MAPTLMNAHTTTP53NPSR1 | |
| SCHEMBL1780626 | 0.89 | LMNA (0.59) | MAPTLMNAHTTTP53NPSR1 | |
| SCHEMBL1780816 | 0.89 | MAPT (0.40) | MAPTLMNAHTTTP53NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563551-B2 | Method for preventing or treating a disease related to the glucocorticoid receptor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-10-22 | — | — | US | disclosed |
| US-8563551-B2 | Method for preventing or treating a disease related to the glucocorticoid receptor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-10-22 | — | — | US | disclosed |
| US-8563551-B2 | Method for preventing or treating a disease related to the glucocorticoid receptor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-10-22 | — | — | US | disclosed |
| EP-2085389-B1 | 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING (SUBSTITUTED PHENYL OR SUBSTITUTED HETEROCYCLIC) CARBONYLOXY LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-09-26 | — | — | EP | disclosed |
| EP-2085389-B1 | 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING (SUBSTITUTED PHENYL OR SUBSTITUTED HETEROCYCLIC) CARBONYLOXY LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-09-26 | — | — | EP | disclosed |
| US-20110263600-A1 | Method for preventing or treating a disease related to the glucocorticoid receptor | SANTEN PHARMACEUTICAL CO., LTD. | 2011-10-27 | — | — | US | disclosed |
| US-20110263600-A1 | Method for preventing or treating a disease related to the glucocorticoid receptor | SANTEN PHARMACEUTICAL CO., LTD. | 2011-10-27 | — | — | US | disclosed |
| US-20110263600-A1 | Method for preventing or treating a disease related to the glucocorticoid receptor | SANTEN PHARMACEUTICAL CO., LTD. | 2011-10-27 | — | — | US | disclosed |
| US-8008497-B2 | 1,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008497-B2 | 1,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008497-B2 | 1,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20090298826-A1 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING (SUBSTITUTED PHENYL OR SUBSTITUTED HETEROCYCLIC) CARBONYLOXY LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-03 | — | — | US | disclosed |
| US-20090298826-A1 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING (SUBSTITUTED PHENYL OR SUBSTITUTED HETEROCYCLIC) CARBONYLOXY LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-03 | — | — | US | disclosed |
| US-20090298826-A1 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING (SUBSTITUTED PHENYL OR SUBSTITUTED HETEROCYCLIC) CARBONYLOXY LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-03 | — | — | US | disclosed |
| EP-2085389-A1 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING (SUBSTITUTED PHENYL OR SUBSTITUTED HETEROCYCLIC) CARBONYLOXY LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS | Santen Pharmaceutical Co., Ltd (JP) | 2009-08-05 | — | — | EP | disclosed |
| EP-2085389-A1 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING (SUBSTITUTED PHENYL OR SUBSTITUTED HETEROCYCLIC) CARBONYLOXY LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS | Santen Pharmaceutical Co., Ltd (JP) | 2009-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298826-A1 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING (SUBSTITUTED PHENYL OR SUBSTITUTED HETEROCYCLIC) CARBONYLOXY LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS | NR3C1, NR3C2, NR5A1 | MAPT 4861/4885LMNA 4460/4885HTT 4825/4885 |
| US-20110263600-A1 | Method for preventing or treating a disease related to the glucocorticoid receptor | NR3C1, NR3C2, MC2R | MAPT 3341/4885LMNA 2023/4885HTT 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.